Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Example Input: Since this story doesn’t make claims about efficacy, costs don’t seem applicable. We give this story a satisfactory score, but the story could have helped readers understand why measuring surrogate markers such as homocysteine levels can be different than tracking true outcomes such as heart attack or stroke. Here, the surrogate endpoint (homocysteine levels) “improved,” but the real endpoint – heart attack and stroke – did not. There is no discussion of any harms associated with consumption of vitamin B supplements, although such harms would occur from vitamin B intake unlike that studied, so this gets a satisfactory grade. Two of the three studies referred to in the journal article are detailed; a brief reference is given for the third. In addition to the discussion of the studies, a quote was pulled from an editorial in the journal that published the studies. No other treatment options for lowering risk of heart attacks or strokes are mentioned. It’s clear from the story that B vitamins have been in use for some time by many people for these purposes. It’s clear from the story that B vitamins have been in use for some time by many people for these purposes. We can’t be sure if the story relied solely or largely on a news release.
Example Output: Study: Heart attacks not cut by B vitamins

Example Input: London’s Metropolitan Police said the company had been charged with seven counts of supplying a medicinal product which was not of the nature or quality specified in the prescription. It was also accused of failing to take all reasonably practicable steps to ensure that patients were not infected by contaminants. The north London company said in a statement: “As founders of ITH we have every sympathy for all the families affected, regardless of the cause. However, we are disappointed by the decision to charge the company and will vigorously defend this case.”  The police investigation was launched in September 2014 following the death of a baby three months earlier at London’s Guy’s and St Thomas’ hospital. The death of a second baby at the same hospital and a third at the Rosie Maternity Hospital in Cambridge, central England, in June 2014 were then also investigated. The inquiry followed an outbreak of a bacterial infection that affected some babies receiving Total Parental Nutrition (TPN), an intravenous feed. The seven babies involved in the investigation, including the three who died, had all received the feed. The investigation established that the cause of death of the first baby could be linked to TPN, although the deaths of the other two were not found to be linked. Five hospitals in total were involved in the investigation, the other three being Russells Hall Hospital in Dudley, Luton and Dunstable Hospital and Lister Hospital in Stevenage, all in central England. ITH Pharma, which was founded in 2008, said it had manufactured more than 1.4-million components of TPN since its launch and was the sole commercial supplier of reactive feeding solutions to the National Health Service. “This product has helped thousands of extremely vulnerable infants survive premature and complex births,” it said. The case is due to start at Westminster Magistrates’ Court in London on Dec. 17.
Example Output: UK police charge pharmaceutical company over hospital baby deaths.

Example Input: The procedures, called by names such as lipodissolve, mesotherapy, lipozap, lipotherapy, or injection lipolysis all involve unproven injections of drugs, the FDA said in a statement. “We are concerned that these companies are misleading consumers,” Dr. Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research, said in a statement. “It is important for anyone who is considering this voluntary procedure to understand that the products used to perform lipodissolve procedures are not approved by the FDA for fat removal.”   The agency issued warning letters to Monarch Medspa in King of Prussia, Pennsylvania; Spa 35 in Boise, Idaho; Medical Cosmetic Enhancements in Chevy Chase, Maryland; Innovative Directions in Health of Edina, Minnesota; PURE Med Spa in Boca Raton, Florida, and All About You Med Spa in Madison, Indiana. The FDA also warned a Brazilian company that markets so-called lipodissolve products on two Web sites: zipmed.net and mesoone.com. “The FDA will notify regulatory authorities in Brazil of this action,” the FDA said in a statement. “The agency has issued an import alert against the zipmed.net and mesoone.com entities to prevent the importation and distribution of unapproved lipodissolve drug products into the United States.”   The treatments usually consist of injections of two drugs called phosphatidylcholine and deoxycholate, the FDA said. “In some cases, other ingredients, including drugs or components of other products like vitamins, minerals and herbal extracts, are added to the mixture,” the agency added. None has been shown to work in credible clinical trials, it said.
Example Output:
"Fat dissolving"" spa treatment no such thing: FDA."